Sai Life Sciences Ltd

Sai Life Sciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) and ESG Databook for the financial year 2025-26. This report, which is part of the Integrated Annual Report, details the company's corporate identity, operations, employee data, and market presence. The company operates as a Contract Research, Development, and Manufacturing (CRDMO) organization, serving global pharmaceutical and biotechnology clients. The report highlights that 96.84% of the company's turnover comes from exports, serving 16 international countries. The company has 3,909 permanent and other employees and 1,315 permanent and other workers. TUV India Private Limited provided reasonable assurance for the BRSR Core Indicators.

Sai Life Sciences Ltd has announced its 27th Annual General Meeting (AGM) will be held on Thursday, September 17, 2026, at 10:30 AM IST via Video Conferencing. The company is also providing a weblink and navigation path for shareholders whose email addresses are not registered, to access the Integrated Annual Report for FY 2025-26. Shareholders are encouraged to update their email addresses with their Depository Participant for future electronic communications.

Sai Life Sciences Ltd has announced its 27th Annual General Meeting (AGM) will be held on Thursday, September 17, 2026, at 10:30 AM IST. The meeting will be conducted virtually via Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with MCA and SEBI circulars. Key agenda items include the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026, and the re-appointment of Mr. Krishnamraju Kanumuri as a director retiring by rotation. The meeting will be deemed to be held at the company's registered office. Shareholders as of September 10, 2026, are eligible to attend. Remote e-voting facilities will be provided by KFin Technologies Limited.

Sai Life Sciences Ltd has announced the details for its 27th Annual General Meeting (AGM), scheduled for Thursday, September 17, 2026, at 10:30 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company will also provide the Integrated Annual Report for FY 2025-26, including financial statements and board reports, to its members. A cut-off date of Thursday, September 10, 2026, has been set for determining voting rights. Remote e-voting will commence on Monday, September 14, 2026, at 9:00 AM IST and conclude on Wednesday, September 16, 2026, at 5:00 PM IST.

Sai Life Sciences Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The company's Board of Directors approved the standalone and consolidated results, which were reviewed by statutory auditors Deloitte Haskins & Sells LLP. The filing also noted the allotment of 506,782 equity shares due to employee stock option exercises. The company operates in the CRDMO segment.

Sai Life Sciences Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results, along with the limited review report from statutory auditors Deloitte Haskins & Sells LLP. The company also noted the allotment of 506,782 equity shares due to employee stock option exercises during the quarter. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations.

Sai Life Sciences Ltd has announced that its Board of Directors will convene on August 6, 2026, to consider and approve the Un-audited Financial Results for the quarter ended June 30, 2026. The results will include both standalone and consolidated figures. Concurrently, the company has closed its trading window from July 1, 2026, to August 8, 2026, for directors, officials, and designated persons to prevent insider trading.

Sai Life Sciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The window will be closed from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Insiders are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Sai Life Sciences Ltd has released the Monitoring Agency Report for the quarter and year ended March 31, 2026, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, issued by CRISIL Ratings Limited, monitors the utilization of IPO proceeds. The report indicates no deviations from the IPO's stated objectives. As of March 31, 2026, ₹345.88 million has been spent out of the ₹401.16 million allocated for issue expenses, with the remaining ₹55.28 million parked in fixed deposits and a public offer account.

Sai Life Sciences Ltd's audited financial results for the year ended March 31, 2026, reveal a revenue from operations of ₹21,532.26 million, compared to ₹16,420.48 million in the previous year. The company's net profit for the year stood at ₹3,414.81 million, up from ₹1,734.62 million in FY25. The Board of Directors approved these results at a meeting held on May 14, 2026. Total assets increased from ₹31,366.63 million in FY25 to ₹36,028.16 million in FY26.